[123I] I-(HE)3-G3

Iodine-123 labeled HER2-targeted imaging agent

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for [123I] I-(HE)3-G3, covering 2025-04-09 to 2025-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 [Phase 1]